Y Zhou1, Y N Zhou2, S X Liu1, J Wang1, R Ji3, X Yan1. 1. Department of Geriatrics (II), The First Hospital of Lanzhou University, Lanzhou, 730000, People's Republic of China. 2. Department of Gastroenterology, The First Hospital of Lanzhou University, No.1 Donggangxi Road, Chengguan District, Lanzhou, 730000, People's Republic of China. v259gx@163.com. 3. Department of Gastroenterology, The First Hospital of Lanzhou University, No.1 Donggangxi Road, Chengguan District, Lanzhou, 730000, People's Republic of China.
Abstract
PURPOSE: PIM kinase is called proto-oncogene, but there are less research on PIM family in colon cancer. This study was designed to explore the prognosis of PIM3 in colon cancer. METHODS: In this study, we downloaded RNA-seq and clinical information of colon cancer from the Gene Expression Omnibus (GEO) database. Kaplan-Meier method was used for analyzing the impact of PIM3 on the survival of patients with colon cancer. Single-factor and multi-factor cox regression analysis were used for verifying the prognostic value of PIM3. Spearman correlation analysis was used for screening PIM3 related genes. Functional enrichment analysis was used for analyzing the biological functions and pathways in which PIM3 related genes may be involved. STRING online tools were used for building a co-expression network. Cytoscape was used for co-expression network visualization. RESULTS: Compared with the low expression group, the patients in the PIM3 high expression group lived longer time. Single-factor and multi-factor cox regression analysis indicated that PIM3 was an independent prognostic factor for colon cancer. Sixty-two PIM3 related genes were screened, and GO and KEGG enrichment analyses suggested that PIM3 related genes might be involved in the MAPK and WNT pathways. The co-expression network showed a strong correlation between PIM3 and MLKL, MYL5, PPP3R1 and other genes. CONCLUSIONS: PIM3 is an independent prognostic factor of colon cancer and may be a target for the diagnosis and treatment of colon cancer.
PURPOSE: PIM kinase is called proto-oncogene, but there are less research on PIM family in colon cancer. This study was designed to explore the prognosis of PIM3 in colon cancer. METHODS: In this study, we downloaded RNA-seq and clinical information of colon cancer from the Gene Expression Omnibus (GEO) database. Kaplan-Meier method was used for analyzing the impact of PIM3 on the survival of patients with colon cancer. Single-factor and multi-factor cox regression analysis were used for verifying the prognostic value of PIM3. Spearman correlation analysis was used for screening PIM3 related genes. Functional enrichment analysis was used for analyzing the biological functions and pathways in which PIM3 related genes may be involved. STRING online tools were used for building a co-expression network. Cytoscape was used for co-expression network visualization. RESULTS: Compared with the low expression group, the patients in the PIM3 high expression group lived longer time. Single-factor and multi-factor cox regression analysis indicated that PIM3 was an independent prognostic factor for colon cancer. Sixty-two PIM3 related genes were screened, and GO and KEGG enrichment analyses suggested that PIM3 related genes might be involved in the MAPK and WNT pathways. The co-expression network showed a strong correlation between PIM3 and MLKL, MYL5, PPP3R1 and other genes. CONCLUSIONS: PIM3 is an independent prognostic factor of colon cancer and may be a target for the diagnosis and treatment of colon cancer.
Authors: Hsu-Ping Kuo; Scott A Ezell; Sidney Hsieh; Karl J Schweighofer; Leo Wk Cheung; Shiquan Wu; Mutiah Apatira; Mint Sirisawad; Karl Eckert; Yu Liang; Jeff Hsu; Chun-Te Chen; Darrin Beaupre; Betty Y Chang Journal: Am J Cancer Res Date: 2016-11-01 Impact factor: 6.166
Authors: W L Allen; P D Dunne; S McDade; E Scanlon; M Loughrey; H Coleman; C McCann; K McLaughlin; Z Nemeth; N Syed; P Jithesh; K Arthur; R Wilson; V Coyle; D McArt; G I Murray; L Samuel; P Nuciforo; J Jimenez; G Argiles; R Dienstmann; J Tabernero; L Messerini; S Nobili; E Mini; K Sheahan; E Ryan; P G Johnston; S Van Schaeybroeck; M Lawler; D B Longley Journal: JCO Precis Oncol Date: 2018-06-13